Sabrina Hogan
6 posts
We’re excited to share that GlioCART, our CAR-T cell therapy project for glioblastoma, was selected for Venture Kick Stage 2, securing CHF 40’000 in support (June 2025). This milestone helps accelerate our translational work towards targeted, durable immunotherapies for GBM.Read more at Venture Kick: GlioCART project page.
Prime News recently interviewed Prof. Dr. Gregor Hutter, head of neurosurgery at University Hospital Basel, about his team’s groundbreaking work on a new immunotherapy for glioblastoma. In the feature, Prof. Hutter explains how the treatment — which will enter clinical trials next spring — could significantly extend survival for patients […]
Our Research Was Featured in University of Basel News! Our team at the University of Basel has developed a promising new approach to treating glioblastoma, one of the most aggressive and deadly brain tumors. The treatment simultaneously targets several key mechanisms that help the tumor grow and evade therapy, attacking […]